Pemetrexed (Alimta) in Patients with Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• S. Jalal, D. Waterhouse, M. Edelman, S. Nattam, R. Ansari, K. Koneru, M. Yu, J. Shen, T. Breen, N. Hanna: Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study from the Hoosier Oncology Group LUN04-78. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• N. Hanna, R. Ansari, S. Bhatia, R. Govindan, D. Bruetman, M. Guarino, W. Fisher, A. White, T. Breen, B. Juliar. Pemetrexed in Patients (pts) with Relapsed Small Cell Lung Cancer (SCLC): A Phase II Study from the Hoosier Oncology Group LUN04-78. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia

Manuscripts/Articles:

• Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W, Masters G, White A, Stover D, Yu M, Hanna N. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol. 2009 Jan;4(1):93-6. doi: 10.1097/JTO.0b013e31818de1e6. See abstract.